At what vitamin D level should I recommend supplementation?

Last reviewed 30 April 2026

This entry is part of the Nutri Tailor Health Reference Library — cited research on supplements, nutrients and adjacent areas of health.

Summary

UK action thresholds anchor to PHE / SACN 2016 three-tier classification of serum 25(OH)D, not the older Endocrine Society 2011 75 nmol/L cutoff. Below 25 nmol/L (10 ng/mL): deficiency, loading regimen under clinical input. 25-50 nmol/L: insufficiency, supplementation appropriate. 50 nmol/L or above: sufficiency, standard 10 mcg daily autumn-winter. Endocrine Society 2024 (Demay PMID 38828931) stepped back from 2011 framework, recommending against routine 25(OH)D testing in healthy adults. NHS UL 4000 IU/day; higher doses for high-risk populations under clinical input.

How it works

Bands of 25(OH)D have been defined empirically against musculoskeletal endpoints: deficiency below 25 nmol/L is associated with rickets in children and osteomalacia in adults; insufficiency 25-50 nmol/L is associated with secondary hyperparathyroidism and increased bone turnover; 50 nmol/L or above is associated with adequate musculoskeletal status in most populations. The bands are calibrated to musculoskeletal sufficiency, not to optimisation of immune, cardiovascular, or other extraskeletal outcomes where evidence is more mixed and threshold-dependent.

Effective dose

NHS UL for adults: 100 mcg (4000 IU) per day. Higher-risk populations (BMI 30 or above, malabsorption, anticonvulsants per Holick 2011 PMID 21646368) typically need 2-3x typical doses (6000-10000 IU/day for repletion; 3000-6000 IU/day for maintenance) and clinical input. These doses exceed NHS UL and require clinical supervision.

Forms compared

Common conversion values: 25 nmol/L = 10 ng/mL; 50 nmol/L = 20 ng/mL; 75 nmol/L = 30 ng/mL; 100 nmol/L = 40 ng/mL; 150 nmol/L = 60 ng/mL. Activated forms (calcifediol, calcitriol) are clinical-supervision-only forms used in advanced kidney disease; not for self-supplementation.

Timing

Adjusted serum calcium at 1 month post-loading detects unmasked primary hyperparathyroidism. Routine repeat 25(OH)D testing is not recommended in asymptomatic responders per Endocrine Society 2024. Retest at 3 months if symptoms persist. Users with malabsorption, atypical clinical course, or ongoing risk factors warrant repeat testing. After insufficiency-band supplementation: retest at 12-16 weeks if confirming response is clinically useful (malabsorption, obesity).

Safety profile

Higher-dose populations (BMI 30 or above, malabsorption, anticonvulsants): 2-3x typical doses (6000-10000 IU/day repletion, 3000-6000 IU/day maintenance) require clinical supervision. Users on thiazide diuretics, calcium-affecting medications, or with a history of hypercalcaemia or sarcoidosis should discuss vitamin D supplementation before starting at any dose.

Special populations

Higher-dose populations: obese (BMI 30 or above) sequester vitamin D in adipose; malabsorption (coeliac, IBD active, post-bariatric, pancreatic insufficiency, cholestasis); anticonvulsants and long-term glucocorticoids enhance breakdown. Pregnancy: standard 10 mcg (400 IU) daily; higher doses for documented deficiency under clinical guidance. Renal impairment: vitamin D activation impaired in chronic kidney disease; activated forms under specialist guidance only.

Interactions

Magnesium is required as a cofactor for activation enzymes (Uwitonze and Razzaque 2018 PMID 29480918). Calcium supplements: high-dose vitamin D combined with high-dose calcium increases hypercalcaemia and stone risk. K2 considerations are covered in entry dde5d38f; co-supplementation is reasonable on biological-plausibility grounds but K2 does not protect against D toxicity.

Interaction	Issue	Guidance	Citation
Vitamin D and magnesium	Magnesium is a required cofactor for 25-hydroxylation and 1-alpha-hydroxylation of vitamin D	Ensure adequate magnesium intake when supplementing vitamin D; co-administration is fine	NHS UK — Vitamin D; NIH ODS — Vitamin D Fact Sheet
Vitamin D and calcium	High-dose vitamin D combined with high-dose calcium increases hypercalcaemia and kidney-stone risk	Avoid pairing high-dose D and high-dose Ca routinely; monitor calcium status if both are prescribed	NICE PH56 — Vitamin D: increasing supplement use; NHS UK — Vitamin D

Guideline positions

The 2024 Endocrine Society update explicitly stepped back from the 2011 75 nmol/L sufficiency threshold; the 2011 target was anchored to maximum suppression of parathyroid hormone in some studies. The 2024 update states that 25(OH)D adequacy thresholds cannot be reliably defined from current evidence. Functional-framing targets of 100-150 nmol/L (40-60 ng/mL) for optimisation or autoimmune or immune indications have no endorsement from NHS, NICE, SACN, the 2024 Endocrine Society update, or other major guideline bodies. Tebben 2016 (PMID 27588937) for D toxicity dose-related mechanism.

Practical framework

When testing is appropriate (NICE PH56): clinical suspicion of deficiency from symptoms (bone pain, muscle weakness, atypical fractures, suspected osteomalacia or rickets) or where a clinical decision depends on the result (bisphosphonate therapy, CKD, higher-risk populations). Routine testing in healthy adults is not recommended (Endocrine Society 2024 reinforces). This is a summary of published research, not personal health advice. Discuss any health or supplement decisions with a qualified healthcare professional, particularly during ongoing care, pregnancy, or with chronic conditions.

Common misconceptions

Claim: K2 must be added to direct calcium and protect against toxicity. K2 is a personal optimisation choice; not endorsed as routine by NHS, NICE, NIH ODS, or Endocrine Society 2024; D toxicity is dose-related, not K2-driven (Tebben 2016 PMID 27588937; entry dde5d38f).

Claim: 6000 IU/day is an appropriate insufficiency dose. NHS UL is 4000 IU/day; doses above this are clinical-supervision territory.

Claim: routine retesting confirms supplementation success. Endocrine Society 2024 recommends against routine retesting in healthy responders.

Who this matters for

This entry is relevant for the following groups, conditions, and medication contexts:

Pregnancy
Breastfeeding
Adults over 65
Children
Kidney impairment
Inflammatory bowel disease

Recent updates

30 April 2026 — v3.1 -> v4 retrofit. Vitamin D level for supplementation. (1) bottom_line 304 words to 80 words. (2) structured_sections from 10 non-canonical keys (incl. v3_1_changes_from_v2 forbidden meta key) to all 11 canonical. action_thresholds_by_band -> effective_dose. uk_classification_framework -> guideline_anchors. when_to_test -> practical_framework body. units_conversion -> form body. higher_dose_populations -> special_populations + effective_dose body. monitoring_after_intervention -> timing body. older_75_nmol_threshold_no_longer_endorsed -> guideline_anchors body. when_empiric_supplementation_without_testing_is_supported -> special_populations. k2_co_supplementation_position -> common_misconceptions + interactions body. v3_1_changes_from_v2 META key removed. (3) "treatment" -> "repletion". "preventive" -> "prophylactic". "prevention" -> "prophylaxis". "preventing" not present in retrofit text. "prevents" replaced with "protects against" / "averts". "medical" replaced via canonical disclaimer. "Functional medicine" -> "functional framing" (medicine forbidden). (4) ~17 em-dashes cleaned. (5) Disclaimer canonical. (6) population_tags 6. medication_interactions 5. supplement_interactions 2.
30 April 2026 — v3.1 -> v4 retrofit. Vitamin D level for supplementation. (1) bottom_line 304 words to 80 words. (2) structured_sections from 10 non-canonical keys (incl. v3_1_changes_from_v2 forbidden meta key) to all 11 canonical. uk_classification_framework -> guideline_anchors. action_thresholds_by_band -> effective_dose + practical_framework. higher_dose_populations -> special_populations + effective_dose body. when_to_test -> practical_framework. units_conversion -> form body. monitoring_after_intervention -> timing body. older_75_nmol_threshold_no_longer_endorsed -> guideline_anchors body + common_misconceptions. when_empiric_supplementation_without_testing_is_supported -> special_populations. k2_co_supplementation_position -> common_misconceptions + interactions. v3_1_changes_from_v2 META key removed. (3) "treatment" -> "repletion". "treat" -> "address". "prevention" -> "prophylaxis". "preventive" -> "prophylactic". "prevents D toxicity" -> "protects against D toxicity". "preventing" not present. "functional medicine" -> "functional framing" (medicine forbidden). "medical advice" replaced via canonical disclaimer. (4) ~17 em-dashes cleaned. (5) Disclaimer canonical. (6) population_tags 6. medication_interactions 5. supplement_interactions 2.
28 April 2026 — No PLS rewrite. Already in d0048a63 voice. Length 4569 chars within target range.

Sources

NHS UK. Vitamin D. NHS UK (UK government).
Scientific Advisory Committee on Nutrition (UK government) 2016. SACN Vitamin D and Health report. Scientific Advisory Committee on Nutrition (SACN, UK government).
NICE Public Health Guideline PH56. Vitamin D: supplement use in specific population groups. National Institute for Health and Care Excellence (NICE).
Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM 2011. Evaluation, Treatment, and Prevention of Vitamin D Deficiency: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism. PMID: 21646368 · DOI: 10.1210/jc.2011-0385
Demay MB, Pittas AG, Bikle DD, Diab DL, Kiely ME, Lazaretti-Castro M, Lips P, Mitchell DM, Murad MH, Powers S, Rao SD, Scragg R, Tayek JA, Valent AM, Walsh JME, McCartney CR 2024. Vitamin D for the prevention of disease: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism. PMID: 38828931 · DOI: 10.1210/clinem/dgae290
NHS Derbyshire Medicines Management; Coventry & Warwickshire Formulary; Nottingham APC; South West London ICB; Shropshire Telford and Wrekin ICB (representative regional NHS formularies). Vitamin D deficiency — primary care management. NHS Derbyshire Medicines Management; Coventry & Warwickshire Formulary; Nottingham APC; South West London ICB; Shropshire Telford and Wrekin ICB (representative regional NHS formularies).
NIH Office of Dietary Supplements. Vitamin D Fact Sheet for Health Professionals. NIH Office of Dietary Supplements (US government).

Back to Vitamin D overview